维得利珠单抗治疗溃疡性结直肠炎效果及对Th22细胞亚群、肠黏膜屏障功能的影响
The effect of vederizumab on ulcerative colitis and its influence on Th22 cell subsets and intestinal mucosal barrier function
刘琪 1张嘉刚 1张海梅 1高丽丽 1李瑾1
作者信息
- 1. 青海省第五人民医院消化内科,青海西宁 810007
- 折叠
摘要
[目的]探究维得利珠单抗在溃疡性结直肠炎患者中的治疗效果及对Th22细胞亚群、肠黏膜屏障功能的影响.[方法]选取86例溃疡性结直肠炎患者,使用随机数字表将患者分为观察组(n=43)与对照组(n=43).对照组患者采取口服美沙拉嗪肠溶片治疗,观察组在对照组基础上联合使用维得利珠单抗.比较2组患者的临床疗效、炎症指标、Th22细胞亚群、肠黏膜屏障功能及安全性.[结果]观察组治疗有效率(93.02％)明显高于对照组(72.09％),观察组与对照组患者临床疗效比较差异有统计学意义(P＜0.05);2组患者的Th22细胞亚群、白细胞介素-6(IL-6)、抗肿瘤坏死因子-α(TNF-α)、白细胞介素-23(IL-23)及降钙素原(PCT)水平均明显降低,观察组显著低于对照组;2组患者的D-乳酸、尿乳果糖/甘露醇(L/M)、二胺氧化酶(DAO)及内毒素(ET)均明显降低,观察组低于对照组,2组比较差异有统计学意义(P＜0.05);2组不良反应总发生率比较差异无统计学意义(P＞0.05).[结论]维得利珠单抗对溃疡性结直肠炎患者的疗效显著,有效降低炎症水平,改善肠道黏膜屏障功能,安全性较高,具有临床实用价值.
Abstract
[Objective]To investigate the therapeutic efficacy of vderizumab in patients with ulcerative colitis and its effect on Th22 cell subsets and intestinal barrier function.[Methods]Eighty-six patients with ulcerative colitis were randomly divided into observation group(n=43)and control group(n=43).Patients in the control group were treated with mesalazine enteric-coated tablets,while patients in the observation group were treated with vederizumab in addition to the control group treatment.The clinical efficacy,in-flammatory index,Th22 cell subsets,intestinal mucosal barrier function and safety were compared between the two groups.[Results]After treatment,there was a significant difference between the two groups(P＜0.05).The effective rate in the observation group(93.02％)was significantly higher than that in the control group(72.09％).The levels of Th22,IL-6,Il-23,TNF-α and PCT in the two groups were significantly low-er than those in the control group(P＜0.05).D-lactic acid,L/M,DAO and ET in the observation group were significantly lower than those in the control group(P＜0.05),and the total incidence of adverse reac-tions was not significantly different between the two groups(P＞0.05).[Conclusion]Vedozumab is effec-tive and safe in the treatment of patients with ulcerative colitis,which can effectively reduce the level of in-flammation and improve the intestinal mucosal barrier function.
关键词
结肠炎,溃疡性/维得利珠单抗/Th22细胞亚群/肠黏膜屏障功能/炎症Key words
ulcerative colitis/vitalizumab/Th22 cell subsets/intestinal mucosal barrier function/inflam-mation引用本文复制引用
出版年
2024
NETL
NSTL
万方数据